We are analyzing https://link.springer.com/chapter/10.1007/978-1-4020-6554-5_5.

Title:
Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells | SpringerLink
Description:
Defects in apoptosis that evolve during the course of cancer progression not only provide cancer cells with intrinsic survival advantage, but also provide inherent resistance to chemotherapeutic agents. Thus, modulation of apoptosis by targeting components of the...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

google, scholar, cas, pubmed, cancer, cell, apoptosis, death, activation, med, cells, biol, pathway, wang, chapter, tumor, chem, bcl, factor, science, dev, nature, nat, proteins, res, therapy, pathways, white, genes, clin, protein, inhibition, growth, function, apoptotic, inhibitor, mol, receptor, targeting, tan, adams, oncogene, suppressor, bhonly, lung, rev, vivo, usa, human, inhibitors,

Topics {✒️}

bcr-abl-expressing hematopoietic progenitors c-kit/pdgfra mutational analysis apo-2l/trail-induced apoptosis anti-growth factor treatments tnf-alpha-mediated cell death bcr-abl-expressing cells bcr-abl gene mutation nuclear factor-nb inhibitors glucocorticoid-induced thymocyte apoptosis suppresses staurosporine-induced apoptosis p42/p44 mapk cascade epidermal growth factor blocks p53-hdm-2 interaction polyarginine-conjugated smac peptide extremity soft-tissue sarcomas potent smac peptido-mimetics month download article/chapter low-molecular-weight compound chronic-phase myeloid leukemia small-cell lung cancer bak-mediated mitochondrial apoptosis hydrocarbon-stapled bh3 helix raf-erk signaling pathway anticancer drug-induced apoptosis haploinsufficient tumor suppressor small-molecule iap inhibitors structure-based computational screening small-molecular weight inhibitor bcl-xl expression raf/mek/erk pathway tumor suppressor function apaf-1/caspase-9 complex initiates scid/nod hu model nerve growth factor bcl-2 family members nf-0b inhibition sensitizes pi3k/akt/mtor pathway anti-fas antibody activate mitochondrial apoptosis induces cell death cytochrome c-dependent activation gefitinib-sensitizing egfr mutations chronic myeloid leukemia small-cell lung mitochondrial death pathway privacy choices/manage cookies tnf receptor superfamilies chronic myelogenous leukemia bcl-xl function human protein homologous

Questions {❓}

Platinum drugs and taxanes: can we overcome resistance?

Schema {🗺️}

ScholarlyArticle:
      headline:Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells
      pageEnd:104
      pageStart:81
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-4020-6554-5.jpg
      genre:
         Biomedical and Life Sciences
         Biomedical and Life Sciences (R0)
      isPartOf:
         name:Programmed Cell Death in Cancer Progression and Therapy
         isbn:
            978-1-4020-6554-5
            978-1-4020-6553-8
         type:Book
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ting-Ting Tan
            affiliation:
                  name:Rutgers University
                  address:
                     name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
                     type:PostalAddress
                  type:Organization
                  name:Rutgers University
                  address:
                     name:Center for Advanced Biotechnology and Medicine, Rutgers University, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eileen White
            affiliation:
                  name:Rutgers University
                  address:
                     name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
                     type:PostalAddress
                  type:Organization
                  name:Cancer Institue of New Jersey
                  address:
                     name:Department of Molecular Biology and Biochemistry, Cancer Institue of New Jersey, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:apoptosis, chemotherapy, targeted therapy, BCL-2 family, death receptors, signal transduction inhibitors
      description:Defects in apoptosis that evolve during the course of cancer progression not only provide cancer cells with intrinsic survival advantage, but also provide inherent resistance to chemotherapeutic agents. Thus, modulation of apoptosis by targeting components of the apoptotic machinery and its regulators to restore apoptotic function is a rational approach for treating cancer. With our increasing knowledge of the mechanisms of apoptosis regulation and of how apoptosis is disabled in cancer cells, numerous novel approaches targeting apoptotic pathways can now be exploited for cancer therapy. While most of these therapies are still in preclinical development, some have shown considerable promise and progressed into the clinic. This chapter summarizes the current knowledge of the apoptotic pathways and provides a selective review on the development of drugs that target the apoptotic machinery.
      datePublished:2008
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Programmed Cell Death in Cancer Progression and Therapy
      isbn:
         978-1-4020-6554-5
         978-1-4020-6553-8
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Rutgers University
      address:
         name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
         type:PostalAddress
      name:Rutgers University
      address:
         name:Center for Advanced Biotechnology and Medicine, Rutgers University, New Brunswick, USA
         type:PostalAddress
      name:Rutgers University
      address:
         name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
         type:PostalAddress
      name:Cancer Institue of New Jersey
      address:
         name:Department of Molecular Biology and Biochemistry, Cancer Institue of New Jersey, New Brunswick, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ting-Ting Tan
      affiliation:
            name:Rutgers University
            address:
               name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
               type:PostalAddress
            type:Organization
            name:Rutgers University
            address:
               name:Center for Advanced Biotechnology and Medicine, Rutgers University, New Brunswick, USA
               type:PostalAddress
            type:Organization
      name:Eileen White
      affiliation:
            name:Rutgers University
            address:
               name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
               type:PostalAddress
            type:Organization
            name:Cancer Institue of New Jersey
            address:
               name:Department of Molecular Biology and Biochemistry, Cancer Institue of New Jersey, New Brunswick, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
      name:Center for Advanced Biotechnology and Medicine, Rutgers University, New Brunswick, USA
      name:Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, USA
      name:Department of Molecular Biology and Biochemistry, Cancer Institue of New Jersey, New Brunswick, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(272)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js

5.04s.

LINK . SPRINGER . COM {}